Dutch Medtech Startup Secures €20 Million to Advance its Robotic Blood Collection Device

Vitestro, an innovative Dutch startup developing autonomous blood drawing technology, has raised €20 million in its latest funding round to accelerate commercialization efforts of its groundbreaking robotic blood collection device. The Series B funding was co-led by medical technology investor Sonder Capital and new investor NYBC Ventures, and also included contributions from Invest-NL and the European Innovation Council Fund.

With over €46 million raised to date, Vitestro plans to use the fresh capital injection to obtain CE marking by the end of 2024 and begin deploying its devices in European hospitals before the end of the year. The company’s revolutionary technology combines artificial intelligence and robotics to provide precise, autonomous blood collection – reducing workload pressures on clinicians while vastly improving the patient experience.

Vitestro’s robotic device utilizes ultrasound imaging and AI-guided needle insertion to collect blood samples with unparalleled accuracy and safety. Early adopters have been impressed by how it streamlines the collection process and eases pressures in overburdened medical laboratories. Having already tested its prototype on over 1,000 individuals, Vitestro is now leading the industry’s largest evaluation of autonomous blood collection technology.